Clinical Trial Update: Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 pilot study investigating ruxolitinib in relapsed or refractory Hodgkin lymphoma and primary mediastinal large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Relapsed or Refractory Hodgkin Lymphoma, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Status: COMPLETED